Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments

European Journal of Human Genetics

Volumn 13, Issue 5, 2005, Pages 641-648

  Tabolacci, Elisabetta ^a   Pietrobono, Roberta ^a   Moscato, Umberto ^a   Oostra, Ben A ^b   Chiurazzi, Pietro ^a   Neri, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chromatin immunoprecipitation; Epigenetic modifications; Fragile X syndrome; Reactivating treatments; Real time PCR

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLCARNITINE; DNA; FRAGILE X MENTAL RETARDATION PROTEIN; HISTONE H3; HISTONE H4; LYSINE;

ACETYLATION; ARTICLE; CHROMATIN; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; EXON; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRINUCLEOTIDE REPEAT;

ACETYLATION; ACETYLCARNITINE; AZACITIDINE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EPIGENESIS, GENETIC; EXONS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HISTONES; HUMANS; MALE; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RNA-BINDING PROTEINS;

EID: 18844398832     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201393     Document Type: Article

References (27)

1. Fu YH, Kuhl DF, Pizzuti A et al: Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991; 67: 1047-1058.
2. Verkerk AJMH, Pieretti M, Sutcliffe JS et al: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting lenght variation in fragile X syndrome. Cell 1991; 65: 905-914.
3. Feng Y, Zhang F, Lokey LK et al: Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995; 268: 731-734.
4. Pieretti M, Zhang F, Fu YH et al: Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991; 66: 817-822.
5. Brown V, Jin P, Ceman S et al: Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001; 107: 477-487.
6. Zalfa F, Bagni C: Molecular insights into mental retardation: multiple functions for the fragile X mental retardation protein? Curr Issues Mol Biol 2004; 6: 73-88.
7. Hagerman RJ, Hull CE, Safanda JF et al: High functioning fragile X males: demonstration of an unmethylated fully expanded FMR1 mutation associated with protein expression. Am J Med Genet 1994; 51: 298-308.
8. Smeets HJ, Smits AP, Verheij CE et al: Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 1995; 4: 2103-2108.
9. Chiurazzi P, Pomponi MG, Willemsen R et al: In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 1998; 7: 109-113.
10. Pietrobono R, Pomponi MG, Tabolacci E et al: Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res 2002; 30: 3278-3285.
11. Jones PL, Veenstra GJC, Wade PA et al: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
12. Nan X, Ng H-H, Johnson CA et al: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
13. Razin A: CpG methylation, chromatin structure and gene silencing - a three-way connection. EMBO J 1998; 17: 4905-4908.
14. Coffee B, Zhang F, Warren ST et al: Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 1999; 22: 98-101.
15. Chiurazzi P, Pomponi MG, Pietrobono R et al: Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 1999; 8: 2317-2323.
16. Turner BM: Cellular memory and the histone code. Cell 2002; 111: 285-291.
17. Grewal SIS, Moazed D: Heterochromatin and epigenetic control of gene expression. Science 2003; 301: 798-802.
18. Lachner M, O'Sullivan RJ, Jenuwein T: An epigenetic road map for histone lysine methylation. J Cell Sci 2003; 116: 2117-2124.
19. Coffee B, Zhang F, Ceman S et al: Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile X syndrome. Am J Hum Genet 2002; 71: 923-932.
20. Pomponi MG, Neri G: Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am J Med Genet 1994; 51: 447-450.
21. Tassone F, Hagerman RJ, Taylor AK et al: Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000; 66: 6-15.
22. Litt MD, Simpson M, Gaszner M et al: Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 2001; 293: 2453-2455.
23. Torrioli MG, Vernacotola S, Mariotti P et al: Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 1999; 87: 366-368.
24. Pascale E, Battiloro E, Reale GC et al: Modulation of methylation in the FMR1 promoter region after long term treatment with L-carnitine and acetyl-L-carnitine. J Med Genet 2003; 40: e76.
25. Cheutin T, McNairn AJ, Jenuwein T et al: Maintenance of stable heterochromatin domains by dynamic HP1 binding. Science 2003; 299: 721-725.
26. Kouzarides T: Histone methylation in transcriptional control. Curr Opin Genet Dev 2002; 12: 198-209.
27. Pietrobono, R, Tabolacci E, Zalfa F et al: Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 2005; 14: 267-277.